Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 3,253 matching trials from the live ClinicalTrials.gov search.

Filters: Not yet recruiting Clear all

Conditions: Diabetes, Kidney Disease, Vascular Disease, Retinopathy
Interventions: Montelukast, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 80 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Post-ect Agitation, Post-ictal Agitation
Interventions: Weighted blanket, Usual Care Group; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Schizoaffective Disorder, Schizophrenia, Bipolar Disorder, Obstructive Sleep Apnea of Adult
Interventions: Automatic Positive Airway Pressure (APAP); Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 40 Years to 70 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Post-Traumatic Stress Disorder, Chronic, Depressed Mood, Depressive and Anxiety Disorders, Anxiety, Depression - Major Depressive Disorder
Interventions: Cognitive Processing Therapy; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 85 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Tumor Infiltrating Lymphocyte, CD8-PET, Advanced Melanoma
Interventions: Crefmirlimb, PET/CT imaging; Drug · Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Liver Tumors
Interventions: RayAblation; Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections, Sexually Transmitted Infection
Interventions: PrEPwise, Usual care; Behavioral · Other
Lead sponsor: Boston University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: High Grade Glioma, Glioblastoma, Gliosarcoma
Interventions: Dexbrompheniramine, Temozolomide; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Parkinson's Disease (PD), PD
Interventions: Injecting KL002 into the bilateral putamen; Genetic
Lead sponsor: Kanglin Biotechnology (Hangzhou) Co., Ltd.; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Anterior Cerebral Artery Syndrome, Anterior Cerebral Artery Stroke, Acute Ischemic Stroke, Cardioembolic Stroke, Vasogenic Cerebral Edema
Interventions: Transcranial Doppler (TCD) examination; Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Malignant Melanoma With Metastasis, Malignant Melanoma, Malignant Melanoma Stage IIIc, Malignant Melanoma Stage IV
Interventions: RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy; Biological · Drug
Lead sponsor: Rapa Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Cerebral Palsy, Hemiplegia, Infantile
Interventions: Arm- and hand-use focused power mobility training; Other
Lead sponsor: Grand Valley State University; Other
Eligibility: 3 Years to 8 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2028 – 2029
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Barrett's Esophagus With Dysplasia
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Androgenetic Alopecia
Interventions: Xtressé Hair Growth Gummies, Placebo Comparator; Other · Dietary Supplement
Lead sponsor: Restore Biologics Holdings, Inc. dba Xtressé; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Marriottsville, Maryland

Conditions: Liver Transplant Recipient, Alcohol Use Disorders (AUD)
Interventions: Online Sober Active Community, Recovery coach; Behavioral
Lead sponsor: Leigh Anne Dageforde; Other
Eligibility: 21 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Athletic Injuries
Interventions: Pre-season strength and conditioning program; Other
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 14 Years to 18 Years
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2028 – 2029
U.S. locations: 1
States / cities: League City, Texas

Conditions: Chronic Insomnia, Sleep Deprivation, REM Behavior Disorder, REM Sleep Behavior Disorder, REM Sleep Measurement, Insomnia, Insomnia Related to Specified Disorder, Insomnia Due to Other Mental Disorder, Insomnia Comorbid to Psychiatric Disorder, Insomnia Due to Anxiety and Fear, Insomnia Related to Another Mental Condition, Insomnia Disorders, Idiopathic Hypersomnia, Sleep Disorders, Circadian Rhythm, Post Trauma Nightmares, PTSD - Post Traumatic Stress Disorder, Sleep Quality, Anesthesia, Anxiety, Depression, Mental Health, Alzheimer Disease or Associated Disorder, Parkinsons, Circadian Rhythm, Circadian Dysregulation, PTSD, Post-Traumatic, Post-Traumatic Stress Disorder Complex, Military Combat Stress Reaction, Sleep, Military Activity, Veterans, Shift Work Sleep Disorder, Menopause Related Conditions, Pain, Cancer Pain, Athletes
Interventions: PROSOMNIA Sleep Therapy™ (PSTx), Anesthesia-Induced Sleep Therapy, Diprivan (propofol), Astra-Zeneca, Continuous EEG Monitoring; Procedure · Drug · Device
Lead sponsor: Nyree Penn; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Aventura, Florida

Conditions: Autism in Children, Autistic Disorder in Children and Adolescents, Autism Spectrum Disorder
Interventions: Ganaxolone (Ztalmy), Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 5 Years to 17 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Stanford, California

Conditions: Mobility Impairment
Interventions: Use of GEL BALL FITTED MODULAR CUSHION, Use of SQUISHINS FITTED MODULAR CUSHION; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Post Traumatic Stress Disorder
Interventions: Standard CPT, CPT-LEAP; Behavioral
Lead sponsor: Boston University; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Jamaica Plain, Massachusetts

Conditions: SCHIZOPHRENIA 1 (Disorder)
Interventions: DSP-2342; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Anxiety, Anxiety Depression, Worry, Depression, Rumination - Thoughts
Interventions: Be Specific, Be Kind, Be Present, Break Habit, Psychoeducation; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Imperial, California

Conditions: Hepatitis Autoimmune Disease, Hepatitis
Interventions: LY3981314; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Indianapolis, Indiana • Dallas, Texas

Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Allogeneic Defined Hematopoietic Stem Cells/Immune Cells, Busulfan, Filgrastim, Fludarabine, Granulocyte Colony-Stimulating Factor, Thiotepa; Biological · Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Sacramento, California

Search by objective public record fields.

MIRACLE-T2D Montelukast Intervention for Renal, Cardiovascular and Eye Health in Type 2 Diabetes

Peri-procedural Weighted Blanket Use for ECT

Obstructive Sleep Apnea Treatment in Serious Mental Illness

An Interrupted Time-Series Pilot Trial of LGBTQ-Affirming Cognitive Processing Therapy for Interpersonal and Developmental Trauma

Optimizing Tumor-Infiltrating Lymphocyte (TIL) Harvest Site and Patient Selection With CD8-PET Imaging in Patients With

Estimating The Rate Of Complete Ablation (A0) With The Use Of Biomechanical Deformable Image Registration

PrEPwise Pilot Among Black Women in Eastern Virginia

Metronomic Temozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblastoma

A Phase 1/2a Clinical Study of KL002 in Treatment of Parkinson's Disease

Transcranial Doppler Evaluation After Endovascular Thrombectomy for Acute Ischemic Stroke (PRECISE-TCD)

Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma

Using Power Mobility Training to Promote Arm & Hand Function in Children With Cerebral Palsy

Ursodeoxycholic Acid in Barrett's Endotherapy

Study to Evaluate Xtressé Gummy Supplement in Women With Thinning Hair

Intervention for Alcohol Use Disorder Recovery After Liver Transplantation

Identification of Neuromusculoskeletal Variables Associated With Injury Risk and Performance in High School Athletes.

Evaluating the Efficacy and Safety of PROSOMNIA Sleep Therapy™ in Patients With Sleep Deprivation and Chronic Insomnia

Clinical Trial Evaluating the Effects of Ganaxolone in Children With Autism

User Evaluation of Advanced Personalized Modular Pressure Relief Seating Cushion Systems

Cognitive Processing Therapy for Posttraumatic Stress Disorder and Co-occurring Lived Experience Stress

Brain Imaging of DSP-2342

Calming Minds Study

A Study of LY3981314 in Participants With Autoimmune Hepatitis

Allogeneic ORCA-Q Stem Cell Transplant for the Treatment of Relapsed and Refractory High Risk Multiple Myeloma